Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research
Abstract Prostate cancer (PCa) ranks as the second most common malignancy and the fifth leading cause of cancer-related deaths among men. A critical challenge lies in accurately identifying those patients at high risk for transitioning rapidly from hormone-sensitive PCa (HSPC) to lethal castration-r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03708-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849769446108823552 |
|---|---|
| author | Chenxi Pan Wei Wang Yi He Bo Yang |
| author_facet | Chenxi Pan Wei Wang Yi He Bo Yang |
| author_sort | Chenxi Pan |
| collection | DOAJ |
| description | Abstract Prostate cancer (PCa) ranks as the second most common malignancy and the fifth leading cause of cancer-related deaths among men. A critical challenge lies in accurately identifying those patients at high risk for transitioning rapidly from hormone-sensitive PCa (HSPC) to lethal castration-resistant PCa (CRPC). In our study, we employed a multiomics approach involving bioinformatics analysis on datasets GSE2443 and GSE35988, along with proteomics studies, to discover that cysteine- and glycine-rich protein 1 (CSRP1) expression significantly impacts the progression of HSPC. This hypothesis was substantiated through experiments using PC3 and LNCaP prostate cancer cells, where we conducted scratch assays and apoptosis assays, all of which confirmed CSRP1’s role in suppressing tumor growth. Furthermore, we elucidated the inhibitory effect of CSRP1 on tumors by performing xenograft experiments on castrated mice models. To solidify these findings in a clinical context, we constructed a nomogram model integrating CSRP1’s immunohistochemistry data and clinical parameters from an actual patient cohort with HSPC. This model revealed that low CSRP1 expression indeed promotes the advancement towards CRPC. In conclusion, the level of CSRP1 expression can serve as a valuable biomarker for clinicians to predict disease progression in their patients. It has the potential to guide personalized clinical management and decision-making strategies, thereby contributing to more effective and targeted treatment approaches for HSPC patients. |
| format | Article |
| id | doaj-art-bdfe0eab00554ad2a28f86d8756dd9b9 |
| institution | DOAJ |
| issn | 1475-2867 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-bdfe0eab00554ad2a28f86d8756dd9b92025-08-20T03:03:24ZengBMCCancer Cell International1475-28672025-02-0125111610.1186/s12935-025-03708-yIdentification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional researchChenxi Pan0Wei Wang1Yi He2Bo Yang3State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, School of Bioengineering, Dalian University of TechnologyDepartment of Urology, The Second Hospital of Dalian Medical UniversityDepartment of Urology, The Second Hospital of Dalian Medical UniversityDepartment of Urology, The Second Hospital of Dalian Medical UniversityAbstract Prostate cancer (PCa) ranks as the second most common malignancy and the fifth leading cause of cancer-related deaths among men. A critical challenge lies in accurately identifying those patients at high risk for transitioning rapidly from hormone-sensitive PCa (HSPC) to lethal castration-resistant PCa (CRPC). In our study, we employed a multiomics approach involving bioinformatics analysis on datasets GSE2443 and GSE35988, along with proteomics studies, to discover that cysteine- and glycine-rich protein 1 (CSRP1) expression significantly impacts the progression of HSPC. This hypothesis was substantiated through experiments using PC3 and LNCaP prostate cancer cells, where we conducted scratch assays and apoptosis assays, all of which confirmed CSRP1’s role in suppressing tumor growth. Furthermore, we elucidated the inhibitory effect of CSRP1 on tumors by performing xenograft experiments on castrated mice models. To solidify these findings in a clinical context, we constructed a nomogram model integrating CSRP1’s immunohistochemistry data and clinical parameters from an actual patient cohort with HSPC. This model revealed that low CSRP1 expression indeed promotes the advancement towards CRPC. In conclusion, the level of CSRP1 expression can serve as a valuable biomarker for clinicians to predict disease progression in their patients. It has the potential to guide personalized clinical management and decision-making strategies, thereby contributing to more effective and targeted treatment approaches for HSPC patients.https://doi.org/10.1186/s12935-025-03708-yHormone-sensitive prostate cancerCysteine- and glycine-rich protein 1WGCNAProteomicsNomogram |
| spellingShingle | Chenxi Pan Wei Wang Yi He Bo Yang Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research Cancer Cell International Hormone-sensitive prostate cancer Cysteine- and glycine-rich protein 1 WGCNA Proteomics Nomogram |
| title | Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research |
| title_full | Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research |
| title_fullStr | Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research |
| title_full_unstemmed | Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research |
| title_short | Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research |
| title_sort | identification of csrp1 as novel biomarker for hormone sensitive prostate cancer by the combination of clinical and functional research |
| topic | Hormone-sensitive prostate cancer Cysteine- and glycine-rich protein 1 WGCNA Proteomics Nomogram |
| url | https://doi.org/10.1186/s12935-025-03708-y |
| work_keys_str_mv | AT chenxipan identificationofcsrp1asnovelbiomarkerforhormonesensitiveprostatecancerbythecombinationofclinicalandfunctionalresearch AT weiwang identificationofcsrp1asnovelbiomarkerforhormonesensitiveprostatecancerbythecombinationofclinicalandfunctionalresearch AT yihe identificationofcsrp1asnovelbiomarkerforhormonesensitiveprostatecancerbythecombinationofclinicalandfunctionalresearch AT boyang identificationofcsrp1asnovelbiomarkerforhormonesensitiveprostatecancerbythecombinationofclinicalandfunctionalresearch |